Search results for "Static"

showing 10 items of 1528 documents

Pseudodominant inheritance of goitrous congenital hypothyroidism caused by TPO mutations: molecular and in silico studies.

2007

CONTEXT AND OBJECTIVE: Most cases of goitrous congenital hypothyroidism (CH) from thyroid dyshormonogenesis 1) follow a recessive mode of inheritance and 2) are due to mutations in the thyroid peroxidase gene (TPO). We report the genetic mechanism underlying the apparently dominant inheritance of goitrous CH in a nonconsanguineous family of French Canadian origin. DESIGN, SETTING, AND PARTICIPANTS: Two brothers identified by newborn TSH screening had severe hypothyroidism and a goiter with increased (99m)Tc uptake. The mother was euthyroid, but the father and two paternal uncles had also been diagnosed with goitrous CH. After having excluded PAX8 gene mutations, we hypothesized that the und…

MaleModels Molecularendocrine systemmedicine.medical_specialtySurface PropertiesEndocrinology Diabetes and MetabolismClinical BiochemistryMolecular Sequence DataStatic ElectricityContext (language use)Gene mutationCompound heterozygosityBiochemistryIodide PeroxidasePolymerase Chain ReactionEndocrinologyThyroid dyshormonogenesisInternal medicineCongenital HypothyroidismMedicineMissense mutationHumansEuthyroidAmino Acid SequenceAlleleGeneticsBase Sequencebusiness.industryGoiterBiochemistry (medical)Infant NewbornDNAmedicine.diseaseCongenital hypothyroidismPedigreeEndocrinologyMutationFemalebusinessSequence AlignmentThe Journal of clinical endocrinology and metabolism
researchProduct

Nitrosoureas Modes of Action and Perspectives in the Use of Hormone Receptor Affine Carrier Molecules

1989

Mechanisms of DNA adduct formation by antineoplastic 2-chloroethyl-N-nitrosoureas (CNUs) and of DNA damage induced by these compounds are discussed. CNUs are alkylating agents that form DNA-DNA cross-links as well as 2-chloroethylated and 2-hydroxyethylated adducts, the N-7-position of guanine being the predominantly alkylated site. A close correlation exists between the potential of a given compound to induce DNA-DNA cross-links and its antineoplastic effectiveness. However, levels of DNA-DNA cross-linking in bone marrow and extent of myelosuppression as measured in rodents are also closely correlated. The design of new cross-linking analogues capable of directing the antineoplastically re…

MaleNeoplasms Hormone-DependentDNA damageGuaninemedicine.medical_treatmentAntineoplastic AgentsReceptors Cell SurfaceNitrosourea CompoundsAdductStructure-Activity Relationshipchemistry.chemical_compoundBone MarrowmedicineAnimalsHumansRadiology Nuclear Medicine and imagingDrug Carriersbusiness.industryMammary Neoplasms ExperimentalProstatic NeoplasmsEstrogensHematologyGeneral MedicineSteroid hormoneOncologyMechanism of actionBiochemistrychemistryHormone receptormedicine.symptombusinessDNAHormoneActa Oncologica
researchProduct

Editorial comment on: Measurement of serum isoform [–2]proPSA derivatives shows superior accuracy to magnetic resonance imaging in the diagnosis of p…

2017

MaleNephrologyGene isoformPathologymedicine.medical_specialtyUrology030232 urology & nephrology03 medical and health sciencesProstate cancer0302 clinical medicineInternal medicinemedicineHumansProtein IsoformsIn patientmedicine.diagnostic_testbusiness.industryProstatic NeoplasmsMagnetic resonance imagingProstate-Specific Antigenmedicine.diseaseMagnetic Resonance ImagingProstate-specific antigenNephrology030220 oncology & carcinogenesisbusinessScandinavian Journal of Urology
researchProduct

Kinetics of serum total and free prostate-specific antigen (PSA) after extended multisite prostate biopsy: Comparison among biopsy, transurethral res…

2008

Abstract Background The kinetics and reproducibility of serum prostate-specific antigen (PSA) following extended multisite biopsies are unknown. The aim of this study was to examine the kinetics of hematogenous leakage of PSA molecules by comparing the postintervention PSA manner among extended biopsies, transurethral resection of the prostate (TURP) and biopsy plus TURP. Methods Total and free PSA values were examined before and sequentially after intervention (at 1 hour, 24 hours, 2 days, 14 days, and 28 days), in patients who underwent 14-core prostate biopsy (Biopsy, n = 53), TURP (TURP, n = 21), or prostate biopsy plus TURP (Biopsy+TURP, n = 18). Results Ten patients in the Biopsy grou…

MaleNephrologymedicine.medical_specialtyProstate biopsyBiopsyUrologymedicine.medical_treatmentUrologyurologic and male genital diseasesProstate cancerProstateInternal medicineBiopsymedicineHumansProspective StudiesAgedTransurethral resection of the prostateAged 80 and overmedicine.diagnostic_testGenitourinary systembusiness.industryProstateTransurethral Resection of ProstateProstatic NeoplasmsMiddle AgedProstate-Specific Antigenmedicine.diseaseSurgeryProstate-specific antigenmedicine.anatomical_structureOncologybusinessUrologic Oncology: Seminars and Original Investigations
researchProduct

How radical prostatectomy procedures have changed over the last 10 years in Italy: a comparative analysis based on more than 1500 patients participat…

2020

Purpose Therapeutic strategies for prostate cancer (PCa) have been evolving dramatically worldwide. The current article reports on the evolution of surgical management strategies for PCa in Italy. Methods The data from two independent Italian multicenter projects, the MIRROR-SIU/LUNA (started in 2007, holding data of 890 patients) and the Pros-IT-CNR project (started in 2014, with data of 692 patients), were compared. Differences in patients' characteristics were evaluated. Multivariable logistic regression models were used to identify characteristics associated with robot-assisted (RA) procedure, nerve sparing (NS) approach, and lymph node dissection (LND). Results The two cohorts did not …

MaleNephrologymedicine.medical_specialtyTime FactorsUrologymedicine.medical_treatment030232 urology & nephrologyLymph node dissectionLogistic regression03 medical and health sciencesProstate cancer0302 clinical medicineInternal medicineLUNA studyBiopsyHumansMedicineProspective StudiesNerve sparingLymph nodeAgedProstatectomyProstate cancermedicine.diagnostic_testbusiness.industryProstatectomyMIRROR SIU/LUNA studyLymph node dissection MIRROR SIU/LUNA study Nerve sparing Pros-IT CNR study Prostate cancer Robotic proceduresProstatic NeoplasmsCancerPros-IT CNR studyMiddle Agedmedicine.diseaseMIRROR SIUDissectionRobotic proceduresLogistic Modelsmedicine.anatomical_structureItaly030220 oncology & carcinogenesisLymph node dissection; MIRROR SIU/LUNA study; Nerve sparing; Pros-IT CNR study; Prostate cancer; Robotic procedures; Aged; Humans; Italy; Logistic Models; Male; Middle Aged; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Time FactorsLymph node dissection; MIRROR SIU/LUNA study; Nerve sparing; Pros-IT CNR study; Prostate cancer; Robotic proceduresbusiness
researchProduct

Plasma hTERT mRNA discriminates between clinically localized and locally advanced disease and is a predictor of recurrence in prostate cancer patients

2012

Since the introduction of prostate-specific antigen (PSA) testing, new prostate cancer (PCa) patients are diagnosed earlier and most have localized and locally advanced disease. Current diagnosis methods lack specificity and sensitivity, leading to overdiagnosis and overtreatment of patients with low-risk organ-confined localized disease. Therefore, new non-invasive molecular tools are needed to discriminate between localized and locally advanced disease.Plasma telomerase reverse transcriptase (hTERT) mRNA levels were determined by qRT-PCR in 49 patients with localized and locally advanced PCa. Diagnostic accuracy and efficacy as a prognostic factor of biochemical recurrence of plasma hTERT…

MaleOncologyBiochemical recurrencemedicine.medical_specialtyPathologyTelomeraseClinical BiochemistryProstate cancerAntigenRecurrenceInternal medicineDrug DiscoveryBiomarkers TumormedicineHumansTelomerase reverse transcriptaseRNA MessengerOverdiagnosisTelomeraseAgedNeoplasm StagingPharmacologybusiness.industryProstatic NeoplasmsMiddle Agedmedicine.diseaseROC CurveArea Under CurveLocalized diseaseLocally advanced diseasebusinessExpert Opinion on Biological Therapy
researchProduct

Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers

2011

Abstract Mast cells (MC) are c-Kit–expressing cells, best known for their primary involvement in allergic reactions, but recently reappraised as important players in either cancer promotion or inhibition. Here, we assessed the role of MCs in prostate tumor development. In prostate tumors from both tumor-prone transgenic adenocarcinoma of the mouse prostate (TRAMP) mice and human patients, MCs are specifically enriched and degranulated in areas of well-differentiated (WD) adenocarcinoma but not around poorly differentiated (PD) foci that coexist in the same tumors. We derived novel TRAMP tumor cell lines, representative of WD and PD variants, and through pharmacologic stabilization or geneti…

MaleOncologyCancer Researchmedicine.medical_specialtyEpithelial-Mesenchymal TransitionMice TransgenicAdenocarcinomaBiologymedicine.disease_causeCell DegranulationMiceProstate cancerProstateCell Line TumorInternal medicineTumor MicroenvironmentmedicineMast CellAnimalsHumansMast CellsReceptors Tumor Necrosis Factor Member 25Tumor microenvironmentAdenocarcinoma; Animals; Carcinoma Neuroendocrine; Cell Degranulation; Cell Line Tumor; Disease Progression; Epithelial-Mesenchymal Transition; Humans; Male; Mast Cells; Matrix Metalloproteinase 9; Mice; Mice Inbred C57BL; Mice Transgenic; Prostatic Neoplasms; Proto-Oncogene Proteins c-kit; Receptors Tumor Necrosis Factor Member 25; Tumor Microenvironment; Cancer Research; OncologyAnimalProstatic NeoplasmsCancermedicine.diseasehumanitiesCarcinoma NeuroendocrineMice Inbred C57BLProto-Oncogene Proteins c-kitmedicine.anatomical_structureMatrix Metalloproteinase 9OncologyTumor progressionProstatic NeoplasmDisease ProgressionAdenocarcinomaCarcinogenesisHumanTramp
researchProduct

A high cannabinoid CB1 receptor immunoreactivity is associated with disease severity and outcome in prostate cancer

2008

In the light of findings indicating that cannabinoids can affect the proliferation of a number of cancer cell types and that cannabinoid receptor expression is higher in prostate cancer cell lines than in non-malignant cells, we investigated whether the level of cannabinoid 1 receptor immunoreactivity (CB(1)IR) in prostate cancer tissues is associated with disease severity and outcome. Formalin-fixed paraffin-embedded non-malignant and tumour tissue samples from patients who were diagnosed with prostate cancer at a transurethral resection for voiding problems were used. CB(1)IR, which was scored in a total of 399 cases, was associated with the epithelial cell membranes, with little staining…

MaleOncologyCancer Researchmedicine.medical_specialtyPathologyPrognostic variableCannabinoid receptormedicine.medical_treatmentAdenocarcinomaProstate cancerReceptor Cannabinoid CB1Internal medicineBiomarkers TumormedicineHumansSurvival rateAgedCell ProliferationProportional Hazards Modelsbusiness.industryProportional hazards modelCell MembraneProstatic NeoplasmsEpithelial Cellsmedicine.diseaseImmunohistochemistrySurvival RateOncologyArea Under CurveCancer cellImmunohistochemistryCannabinoidbusinessEuropean Journal of Cancer
researchProduct

Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival.

2016

Venous thromboembolism (VTE) is common in cancer patients. However, little is known about VTE risk in metastatic urothelial carcinoma or variant histologies (UC/VH). We sought to characterize the incidence, associative factors, including whether various chemotherapy regimens portend different risk, and impact of VTE on survival in metastatic UC/VH patients. Patients diagnosed with metastatic UC/VH from 2000 to 2013 were included in this multicenter retrospective, international study from 29 academic institutions. Cumulative and 6-month VTE incidence rates were determined. The association of first-line chemotherapy (divided into six groups) and other baseline characteristics on VTE were anal…

MaleOncologyCancer Researchmedicine.medical_treatmentDisease030204 cardiovascular system & hematologyDeoxycytidine0302 clinical medicineNeoplasm MetastasisOriginal ResearchIncidenceIncidence (epidemiology)Middle AgedPrognosis3. Good healthOncology030220 oncology & carcinogenesischemotherapy survivalbladder cancerFemaleBufeta -- Càncermedicine.drugAdultmedicine.medical_specialtyMetastatic Urothelial Carcinomavenous thromboembolismAntineoplastic Agents[SDV.CAN]Life Sciences [q-bio]/Cancer03 medical and health sciencesInternal medicineUrothelialmedicineHumansRadiology Nuclear Medicine and imagingcardiovascular diseasesAgedRetrospective StudiesTrombosi -- TractamentGynecologyCisplatinCarcinoma Transitional CellChemotherapyBladder cancerbusiness.industryClinical Cancer ResearchCancermedicine.diseaseequipment and suppliesSurvival AnalysisGemcitabineGemcitabineUrinary Bladder NeoplasmsUrothelial;Cisplatinbusiness
researchProduct

Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Cancer Treated With Bisphosphonates and Targeted Agents: Results of an Italian Multic…

2015

Osteonecrosis of the jaw (ONJ) associated with the use of bisphosphonates has been rarely reported in metastatic renal cell cancer (RCC) patients. Since the introduction of combined therapies consisting of nitrogen-containing bisphosphonates (NBPs) and targeted agents, an increasing number of RCC patients were reported to develop ONJ, suggesting that therapeutic angiogenesis suppression might increase the risk of ONJ in NBPs users. We performed a multicenter retrospective study and reviewed literature data to assess the occurrence and to investigate the nature of ONJ in RCC patients taking NBPs and targeted agents. Nine Italian Centers contributed to the data collection. Patients with expos…

MaleOncologyIndolesAngiogenesis InhibitorsPyrroleBevacizumab; m-TOR inhibitor; Sorafenib; Sunitinib; Zoledronic acidRetrospective StudieAntineoplastic Combined Chemotherapy ProtocolsSunitinibAged 80 and overDiphosphonatesSunitinibImidazolesOsteonecrosisKidney NeoplasmMiddle AgedSorafenibKidney NeoplasmsBevacizumabDiphosphonateItalyOncologyOsteonecrosiFemaleAngiogenesis InhibitorHumanmedicine.drugSorafenibmedicine.medical_specialtyBevacizumab; m-TOR inhibitor; Sorafenib; Sunitinib; Zoledronic acid; Aged; Aged 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma Renal Cell; Diphosphonates; Female; Humans; Imidazoles; Indoles; Italy; Jaw; Kidney Neoplasms; Male; Middle Aged; Osteonecrosis; Pyrroles; Retrospective Studies; Oncology; UrologyBevacizumabUrologyInternal medicinemedicineHumansPyrrolesIn patientMetastatic renal cell cancerImidazoleCarcinoma Renal CellZoledronic acidAgedRetrospective StudiesAntineoplastic Combined Chemotherapy Protocolbusiness.industryRetrospective cohort studymedicine.diseasem-TOR inhibitorSurgeryZoledronic acidJawIndolebusinessOsteonecrosis of the jaw
researchProduct